

ASX Announcement

For immediate release

24 April 2018

CommSec Executive Series Interview - Bluechiip Managing Director, Andrew McLellan

Andrew McLellan, Bluechiip Limited Managing Director, was recently interviewed as part of the CommSec Executive Series. In the interview Andrew McLellan explains the Company's technology, progress with Original Equipment Manufacturers (OEMs) and other recent initiatives.

A video recording of the interview can be accessed here:

https://www.bluechiip.com/investor/company-overview/

END

For more information contact

Andrew McLellan Managing Director / CEO Ph: +61 457 823 470 andrew.mclellan@bluechiip.com

Media

Richard Allen Ph: +61 3 9915 6341 Oxygen Financial PR



ASX Announcement

For immediate release

24 April 2018

About Bluechiip Limited

Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip® technology does not. Unlike labels, barcodes and RFID, the bluechiip® technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip® technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip® offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip® tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip® technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at www.bluechiip.com